百特与Chatham Therapeutics合作开展血友病B基因治疗

Pharmadeals Review Pub Date : 2012-06-15 DOI:10.3833/PDR.V2012I6.1754

Heather Cartwright

{"title":"百特与Chatham Therapeutics合作开展血友病B基因治疗","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1754","DOIUrl":null,"url":null,"abstract":"Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology. Baxter has paid US$25 M upfront to advance Chatham’s haemophilia B programme through early clinical trials and has global marketing and commercialisation rights to resulting therapies.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I6.1754\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology. Baxter has paid US$25 M upfront to advance Chatham’s haemophilia B programme through early clinical trials and has global marketing and commercialisation rights to resulting therapies.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I6.1754\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

百特国际与Chatham Therapeutics (Asklepios biopharmactical的子公司)签署了一项独家的全球开发和商业化协议，利用Chatham的生物纳米粒子™基因治疗技术治疗血友病B。百特已预付2500万美元，通过早期临床试验推进Chatham的血友病B项目，并拥有由此产生的疗法的全球营销和商业化权利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration

Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology. Baxter has paid US$25 M upfront to advance Chatham’s haemophilia B programme through early clinical trials and has global marketing and commercialisation rights to resulting therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量